4.6 Article

Hepatectomy risk assessment with functional magnetic resonance imaging (HEPARIM)

Journal

BMC CANCER
Volume 21, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12885-021-08830-4

Keywords

Post hepatectomy liver failure; Risk assessment; Functional MRI; Gadoxetate; Indocyanine green; Future liver remnant

Categories

Funding

  1. Medical Research Council (MRC) [MR/P023398/1]
  2. Medical Research Council
  3. MRC [MR/P023398/1] Funding Source: UKRI

Ask authors/readers for more resources

The HEPARIM trial aims to predict post hepatectomy liver failure risk more accurately using MRI biomarkers. The study utilizes an observational cohort design and multivariate analysis to derive prediction models for safer surgical decisions for patients.
Background: Post hepatectomy liver failure (PHLF) remains a significant risk in patients undergoing curative liver resection for cancer, however currently available PHLF risk prediction investigations are not sufficiently accurate. The Hepatectomy risk assessment with functional magnetic resonance imaging trial (HEPARIM) aims to establish if quantitative MRI biomarkers of liver function & perfusion can be used to more accurately predict PHLF risk and FLR function, measured against indocyanine green (ICG) liver function test. Methods: HEPARIM is an observational cohort study recruiting patients undergoing liver resection of 2 segments or more, prior to surgery patients will have both Dynamic Gadoxetate-enhanced (DGE) liver MRI and ICG testing. Day one post op ICG testing is repeated and R15 compared to the Gadoxetate Clearance (GC) of the future liver remnant (FLR-GC) as measure by preoperative DGE- MRI which is the primary outcome, and preoperative ICG R15 compared to GC of whole liver (WL-GC) as a secondary outcome. Data will be collected from medical records, biochemistry, pathology and radiology reports and used in a multi-variate analysis to the value of functional MRI and derive multivariant prediction models for future validation. Discussion: If successful, this test will potentially provide an efficient means to quantitatively assess FLR function and PHLF risk enabling surgeons to push boundaries of liver surgery further while maintaining safe practice and thereby offering chance of cure to patients who would previously been deemed inoperable. MRI has the added benefit of already being part of the routine diagnostic pathway and as such would have limited additional burden on patients time or cost to health care systems. (Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging - Full Text View -, n.d.)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available